Skip to main content

Table 2 Molecular features of responders to nivolumab

From: Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

 

Assessed

Detected

Responder

Non-responder

ORR

P-value

HER2+

71

16 (23%)

1

15

6%

0.12

PD-L1+ in tumor cell

60

14 (23%)

8

6

57%

< 0.01

CPS≥10

60

17 (28%)

6

11

35%

0.17

CPS≥1

60

54 (90%)

14

40

26%

0.15

EBV+

68

4 (6%)

1

3

25%

0.82

MMR-D

68

8 (12%)

6

2

75%

< 0.01

TMB≥10

54

32 (59%)

7

25

22%

0.44

ARID1A mutation

52

5 (10%)

1

4

25%

0.96

ERBB2 mutation

52

2 (4%)

0

2

0%

0.48

KRAS mutation

52

4 (8%)

0

4

0%

0.31

MET mutation

52

2 (4%)

0

2

0%

0.48

PIK3CA mutation

52

9 (17%)

4

5

44%

0.03

TP53 mutation

52

28 (54%)

6

22

21%

0.66

CCNE1 amplification

52

7 (13%)

2

5

29%

0.50

ERBB2 amplification

52

9 (17%)

0

9

0%

0.11

FGFR amplification

52

3 (6%)

0

3

0%

0.38

MDM2 amplification

52

2 (4%)

0

2

0%

0.48

MYC amplification

52

3 (6%)

0

3

0%

0.38

  1. CPS combined positive score, EBV Epstein-Barr virus, MMR-D mismatch repair deficient, ORR objective response rate, PD-L1 programmed cell death-1 ligand-1, TMB tumor mutation burden
Back to article page